EXACT SCIENCES CORP (EXAS) Stock News
NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
EXAS Latest News, Press Relases and Analysis
Hologic Climbs 13% in a Month: How Should You Play the Stock?
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: CRSP
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
Exact Sciences ends the first quarter of 2025 on a solid note.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
Exact Sciences to Participate in June Investor Conference
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Exact Sciences Corporation (EXAS) Slid on Fear of Competition
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due […]
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
Exact Sciences has helped increase colorectal cancer detection. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method.
Will Palantir Stock Join The $1 Trillion Market Cap Club by 2030? The Answer May Surprise You.
Investors are bullish on this AI defense contractor. The numbers tell a different story.
This Top High-Yield Dividend Stock Has a Brilliant Strategy to Capitalize on This Growing Value Disconnect
Brookfield Renewable is always looking for opportunities to grow value for its shareholders. It's seeing a widening disconnect between public and private market values for renewable energy assets. Brookfield is capitalizing on this opportunity through its smart capital recycling strategy.
Exact Sciences Earns 2025 Great Place To Work® Certification™
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.
Exact Sciences to Participate in May Investor Conference
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 43.24% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: RGNX
Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.
The company hiked its sales guidance for the year, but reported steeper-than-expected first-quarter losses.
Exact Sciences Announces First-Quarter 2025 Results
Is The Trade Desk, Inc. (TTD) a Stock That Should Double in 3 Years?
We recently published a list of the 30 Stocks That Should Double in 3 Years. In this article, we are going to take a look at where The Trade Desk, Inc. (NASDAQ:TTD) stands against other stocks that should double in 3 years. On April 25, Kari Firestone, Aureus Asset Management executive chairman and co-founder, joined […]
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CERT
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: REGN